Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma

Abstract

These results suggested that EREG is one of the molecules involved in glioma malignancy, and EGFR inhibitors may be a candidate therapeutic agent for EREG-overexpressing GBM patients.